Drug Trial Radar · NCT04939441
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Apr 20, 2021
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Jidong JiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing Ditan Hospital; ShuGuang Hospital; Huashan Hospital; Tianjin Second People's Hospital; Ruijin Hospital; Tianjin Third Central Hospital; The Ninth Hospital of Nanchang; Beijing YouAn Hospital; The Fifth People's Hospital of Suzhou
- First posted
- Jun 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tenofovir alafenamide (TAF) is a new prodrug of tenofovir developed to treat patients with chronic hepatitis B virus (HBV) infection. Whereas, the long-term effect of TAF to liver fibrosis is still unknown. Here, we enrolled treatment naive CHB patients with biopsy-proven significant fibrosis (METAVIR fibrosis stage ≥ F2). To characterize longitudinal histological changes and assess liver fibrosis regression, the second and third liver biopsies are planned at weeks 96 and 240, respectively. During this study, all subjects will be assessed for laboratory tests, imaging examination at baseline, first 12-week and every 24-week during follow-up.
Conditions
- Chronic Hepatitis B
Interventions
Tenofovir alafenamideDrug
Subjects will be treated for 240 weeks with TAF \[Vemlidy® 25mg QD\] monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with fibrosis regressionTime frame: Week 96 and 240
- HBV DNA undetectable rateTime frame: Week 96
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Beijing YouAn Hospital, Capital Medical University
Beijing, China · Recruiting
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China · Recruiting
The Ninth Hospital of Nanchang
Nanchang, Jiangxi, China · Recruiting
Shuguang Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Huashan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Ruijin Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Tianjin Third Central Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Tianjin Second People's Hospital
Tianjin, Tianjin Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.